Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the...
FOR IMMEDIATE RELEASE Every patient deserves a treatment they know will work for them.” ~ Reg Seeto, CEO, Scipher Medicine BURLINGTON, MA, UNITED STATES /EINPresswire.com/ — Scipher Medicine, a leader in precision medicine for autoimmune diseases, today...
FOR IMMEDIATE RELEASE Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development Baltimore, MD, March 10th, 2026 — Scipher Medicine and Senelix today announced a strategic collaboration to incorporate Scipher’s AI network platform to...
BURLINGTON, Mass.–(BUSINESS WIRE)–Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, today announced a strategic collaboration with Maxymune Therapeutics, a biotechnology company focused on research and development of novel...
WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, a leader in precision immunology, today announced the public launch of ClinicalTrialRank.com, an innovative artificial intelligence (AI) platform engineered to predict clinical trial failure with...
NEW YORK & WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, a leader in precision immunology, and Savant Bio, a Roivant-backed health data infrastructure company, today announced an expanded strategic partnership to build the world’s most advanced...
